Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996507 | 0.97 | PLA2G2A (0.43) | MAPTPTGER3RXFP1TP53FAAH | |
| SCHEMBL3008418 | 0.95 | PTGER3 (0.41) | MAPTPTGER3RXFP1TP53FAAH | |
| SCHEMBL2999341 | 0.95 | FAAH (0.48) | MAPTPTGER3RXFP1TP53FAAH | |
| SCHEMBL4088421 | 0.94 | PLA2G2A (0.43) | MAPTPTGER3TP53FAAHPLA2G2A | |
| SCHEMBL3002874 | 0.93 | PTGS2 (0.46) | MAPTPTGER3RXFP1TP53FAAH | |
| SCHEMBL3001465 | 0.92 | PLA2G2A (0.44) | TP53FAAHPLA2G2ANPC1RAB9A | |
| SCHEMBL2996462 | 0.91 | KCNH2 (0.45) | MAPTRXFP1TP53FAAHHTT | |
| SCHEMBL3004516 | 0.91 | MAPT (0.51) | MAPTPTGER3RXFP1TP53FAAH | |
| SCHEMBL3006717 | 0.90 | THRB (0.42) | MAPTTP53FAAHHTTRAB9A | |
| SCHEMBL2995848 | 0.90 | KMT2A (0.45) | MAPTRXFP1FAAHHTTPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | MAPT 997/4885PTGER3 95/4885RXFP1 377/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | MAPT 2737/4885PTGER3 42/4885RXFP1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.